SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / September 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.
LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").
